Using the early protein HIV Nef, new HLA class I binding epitopes of importance for immune responses to HIV were predicted for common African alleles. In total we identified 45 epitopes previously not described for the HLA alleles A*30:01, A*30:02, B*58:01, and C*07:01 and compared them to reported epitopes, primarily from HLA-A*02:01, from the Los Alamos database and our own vaccine studies. Related to its small size, the Nef gene/protein appears to be able to contribute effectively to confer both stronger and broader cellular immunogenicity to an HIV-1 vaccine. We also propose feasible mutations of such an additional vaccine antigen to preserve its immunogenicity, modified not to confer HLA or CD4+ down-regulating activities. This article includes data on a valuable HIV immunogenic component for a vaccine in Africa.
Get full access to this article
View all access options for this article.
References
1.
CurrierJR, VisawapokaU, TovanabutraS, et al.: CTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: Use of multiple peptide sets increases the detectable breadth of the CTL response. BMC Immunol, 2006; 7:8.
2.
WalkerB and McMichaelA: The T-cell response to HIV. Cold Spring Harb Perspect Med, 2012; 2:doi:10.1101/cshperspect.a007054.
3.
DemersKR, ReuterMA, and BettsMR: CD8(+) T-cell effector function and transcriptional regulation during HIV pathogenesis. Immunol Rev, 2013; 254:190–206.
4.
RobinsonJ, HalliwellJA, McWilliamH, et al.: The IMGT/HLA database. Nucleic Acids Res, 2013; 41:D1222–1227.
Gonzalez-GalarzaFF, ChristmasS, MiddletonD, et al.: Allele frequency net: A database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res, 2011; 39:D913–919.
7.
AddoMM, YuXG, RathodA, et al.: Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load comprehensive epitope A. J Virol, 2003; 77:2081–2092.
8.
FerreAL, LemongelloD, HuntPW, et al.: Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers. J Virol, 2010; 84:10354–10365.
9.
ChakrabortyS, RahmanT, ChakravortyR, et al.: HLA supertypes contribute in HIV type 1 cytotoxic t lymphocyte epitope clustering in Nef and Gag proteins. AIDS Res Hum Retroviruses, 2013; 29:270–278.
10.
SandbergJK, LeanderssonAC, DevitoC, et al.: Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization. Virology, 2000; 273:112–119.
11.
PérezCL, LarsenMV, GustafssonR, et al.: Broadly immunogenic HLA class I supertype-restricted elite CTL epitopes recognized in a diverse population infected with different HIV-1 subtypes. J Immunol, 2008; 180:5092–5100.
12.
CalarotaS, BrattG, NordlundS, et al.: Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet, 1998; 351:1320–1325.
13.
AikenC, KonnerJ, LandauNR, et al.: Nef induces CD4 endocytosis: Requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell, 1994; 76:853–864.
14.
CohenGB, GandhiRT, DavisDM, et al.: The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity, 1999; 10:661–671.
15.
LeonardJA, FilzenT, CarterCC, et al.: HIV-1 Nef disrupts intracellular trafficking of major histocompatibility complex class I, CD4, CD8, and CD28 by distinct pathways that share common elements. J Virol, 2011; 85:6867–6881.
16.
MwimanziP, MarkleTJ, UenoT, et al.: Human leukocyte antigen (HLA) class I down-regulation by human immunodeficiency virus type 1 negative factor (HIV-1 Nef): What might we learn from natural sequence variants?. Viruses, 2012; 4:1711–1730.
17.
TribleRP, Emert-SedlakL, and SmithgallTE: HIV-1 Nef selectively activates Src family kinases Hck, Lyn, and c-Src through direct SH3 domain interaction. J Biol Chem, 2006; 281:27029–27038.
18.
GómezCE, NájeraJL, JiménezEP, et al.: Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine, 2007; 25:2863–2885.
19.
HammerSM, SobieszczykME, JanesH, et al.: Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med, 2013; 369:2083–92.
20.
FellayJ, FrahmN, ShiannaKV, et al.: Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial. J Infect Dis, 2011; 203:773–779.
21.
NielsenM, LundegaardC, BlicherT, et al.: Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. PLoS Comput Biol, 2008; 4:e1000107.
22.
HoofI, PetersB, SidneyJ, et al.: NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics, 2009; 61:1–13.
23.
NielsenM, LundegaardC, BlicherT, et al.: NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One, 2007; 2:e796.
NielsenM, LundegaardC, WorningP, et al.: Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci, 2003; 12(5):1007–1017.
26.
LundegaardC, LamberthK, HarndahlM, et al.: NetMHC-3.0: Accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res, 2008; 36:W509–512.
27.
PetersB and SetteA: Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics, 2005; 6:132.
28.
SidneyJ, AssarssonE, MooreC, et al.: Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res, 2008; 4:2.
29.
NielsenM, LundegaardC, LundO, et al.: The role of the proteasome in generating cytotoxic T-cell epitopes: Insights obtained from improved predictions of proteasomal cleavage. Immunogenetics, 2005; 57:33–41.
30.
PetersB, BulikS, TampeR, et al.: Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J Immunol, 2003; 171:1741–1749.
31.
StranzlT, LarsenMV, LundegaardC, et al.: NetCTLpan: Pan-specific MHC class I pathway epitope predictions. Immunogenetics, 2010; 62:357–368.
32.
MeuwissenPJ, StolpB, IannucciV, et al.: Identification of a highly conserved valine-glycine-phenylalanine amino acid triplet required for HIV-1 Nef function. Retrovirology, 2012; 9:34.
33.
AlemanS, LeitnerT, LiuMA, et al.: Minor nef gene alterations after human HIV-DNA immunisation. AIDS, 2004; 18:815–827.
34.
RajapaksaUS, LiD, PengY-C, et al.: HLA-B may be more protective against HIV-1 than HLA-A because it resists negative regulatory factor (Nef) mediated down-regulation. Proc Natl Acad Sci USA, 2012; 109:13353–13358.
35.
CarringtonM and O'BrienSJ: The influence of HLA genotype on AIDS. Annu Rev Med, 2003; 54:535–551.
36.
KulpaDA and CollinsKL: The emerging role of HLA-C in HIV-1 infection. Immunology, 2011; 134:116–122.
37.
Axelsson-RobertsonR, LoxtonAG, WalzlG, et al.: A broad profile of co-dominant epitopes shapes the peripheral Mycobacterium tuberculosis specific CD8+ T-cell immune response in South African patients with active tuberculosis. PLoS One, 2013; 8:e58309.
38.
MoshaF, UrassaW, AboudS, et al.: Prevalence of genotypic resistance to antiretroviral drugs in treatment-naive youths infected with diverse HIV type 1 subtypes and recombinant forms in Dar es Salaam, Tanzania. AIDS Res Hum Retroviruses, 2011; 27:377–382.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
